0000000000783861

AUTHOR

Amelia Paglia

showing 1 related works from this author

Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study

2005

5060 Background: Cyclooxygenase-2 (COX-2) expression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer (OC). Celecoxib, an orally active COX-2 inhibi...

OncologyCancer ResearchPoor prognosisChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchmedicine.diseaseCarboplatinchemistry.chemical_compoundOrally activeOncologychemistryInternal medicinemedicineCelecoxibOvarian cancerbusinessRecurrent Ovarian Carcinomamedicine.drugJournal of Clinical Oncology
researchProduct